PEDIATRIX MEDICAL GROUP INC (MD) Stock Fundamental Analysis

USA New York Stock Exchange NYSE:MD • US58502B1061

20.76 USD
-0.13 (-0.62%)
Last: Feb 10, 2026, 09:49 AM
Fundamental Rating

5

Overall MD gets a fundamental rating of 5 out of 10. We evaluated MD against 102 industry peers in the Health Care Providers & Services industry. Both the profitability and the financial health of MD get a neutral evaluation. Nothing too spectacular is happening here. MD is valued quite cheap, while showing a decent growth score. This is a good combination! These ratings could make MD a good candidate for value investing.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • MD had positive earnings in the past year.
  • MD had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: MD reported negative net income in multiple years.
  • In the past 5 years MD always reported a positive cash flow from operatings.
MD Yearly Net Income VS EBIT VS OCF VS FCFMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M -1B

1.2 Ratios

  • MD has a better Return On Assets (7.37%) than 89.22% of its industry peers.
  • The Return On Equity of MD (18.21%) is better than 87.25% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 10.25%, MD belongs to the top of the industry, outperforming 80.39% of the companies in the same industry.
  • MD had an Average Return On Invested Capital over the past 3 years of 7.83%. This is in line with the industry average of 9.11%.
  • The 3 year average ROIC (7.83%) for MD is below the current ROIC(10.25%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 7.37%
ROE 18.21%
ROIC 10.25%
ROA(3y)-1.5%
ROA(5y)-4.7%
ROE(3y)-4.21%
ROE(5y)-20.91%
ROIC(3y)7.83%
ROIC(5y)7.13%
MD Yearly ROA, ROE, ROICMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80 -100

1.3 Margins

  • With an excellent Profit Margin value of 8.44%, MD belongs to the best of the industry, outperforming 89.22% of the companies in the same industry.
  • The Operating Margin of MD (12.20%) is better than 83.33% of its industry peers.
  • MD's Operating Margin has declined in the last couple of years.
Industry RankSector Rank
OM 12.2%
PM (TTM) 8.44%
GM N/A
OM growth 3Y-7.13%
OM growth 5Y-6.94%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MD Yearly Profit, Operating, Gross MarginsMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80

5

2. Health

2.1 Basic Checks

  • MD has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • The number of shares outstanding for MD has been increased compared to 1 year ago.
  • Compared to 5 years ago, MD has more shares outstanding
  • MD has a worse debt/assets ratio than last year.
MD Yearly Shares OutstandingMD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
MD Yearly Total Debt VS Total AssetsMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

2.2 Solvency

  • MD has an Altman-Z score of 2.15. This is not the best score and indicates that MD is in the grey zone with still only limited risk for bankruptcy at the moment.
  • MD has a Altman-Z score of 2.15. This is comparable to the rest of the industry: MD outperforms 53.92% of its industry peers.
  • MD has a debt to FCF ratio of 2.20. This is a good value and a sign of high solvency as MD would need 2.20 years to pay back of all of its debts.
  • MD has a Debt to FCF ratio of 2.20. This is in the better half of the industry: MD outperforms 78.43% of its industry peers.
  • A Debt/Equity ratio of 0.65 indicates that MD is somewhat dependend on debt financing.
  • MD's Debt to Equity ratio of 0.65 is in line compared to the rest of the industry. MD outperforms 55.88% of its industry peers.
  • Although MD does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0.65
Debt/FCF 2.2
Altman-Z 2.15
ROIC/WACC1.16
WACC8.81%
MD Yearly LT Debt VS Equity VS FCFMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.3 Liquidity

  • A Current Ratio of 1.83 indicates that MD should not have too much problems paying its short term obligations.
  • MD has a better Current ratio (1.83) than 71.57% of its industry peers.
  • A Quick Ratio of 1.83 indicates that MD should not have too much problems paying its short term obligations.
  • With a decent Quick ratio value of 1.83, MD is doing good in the industry, outperforming 74.51% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.83
Quick Ratio 1.83
MD Yearly Current Assets VS Current LiabilitesMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

4

3. Growth

3.1 Past

  • MD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 56.92%, which is quite impressive.
  • The earnings per share for MD have been decreasing by -15.01% on average. This is quite bad
  • Looking at the last year, MD shows a decrease in Revenue. The Revenue has decreased by -4.21% in the last year.
  • MD shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.49% yearly.
EPS 1Y (TTM)56.92%
EPS 3Y-2.95%
EPS 5Y-15.01%
EPS Q2Q%52.27%
Revenue 1Y (TTM)-4.21%
Revenue growth 3Y1.74%
Revenue growth 5Y2.49%
Sales Q2Q%-3.58%

3.2 Future

  • Based on estimates for the next years, MD will show a small growth in Earnings Per Share. The EPS will grow by 7.64% on average per year.
  • MD is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.71% yearly.
EPS Next Y44.07%
EPS Next 2Y22.97%
EPS Next 3Y16.76%
EPS Next 5Y7.64%
Revenue Next Year-4.52%
Revenue Next 2Y-0.98%
Revenue Next 3Y0.1%
Revenue Next 5Y2.71%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
MD Yearly Revenue VS EstimatesMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 1B 2B 3B
MD Yearly EPS VS EstimatesMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 1 2 3 4

9

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 10.18, the valuation of MD can be described as reasonable.
  • 91.18% of the companies in the same industry are more expensive than MD, based on the Price/Earnings ratio.
  • When comparing the Price/Earnings ratio of MD to the average of the S&P500 Index (28.06), we can say MD is valued rather cheaply.
  • With a Price/Forward Earnings ratio of 9.21, the valuation of MD can be described as very reasonable.
  • MD's Price/Forward Earnings ratio is rather cheap when compared to the industry. MD is cheaper than 92.16% of the companies in the same industry.
  • MD is valuated cheaply when we compare the Price/Forward Earnings ratio to 27.86, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 10.18
Fwd PE 9.21
MD Price Earnings VS Forward Price EarningsMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • MD's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. MD is cheaper than 85.29% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, MD is valued cheaply inside the industry as 92.16% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 6.52
EV/EBITDA 7.03
MD Per share dataMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of MD may justify a higher PE ratio.
  • A more expensive valuation may be justified as MD's earnings are expected to grow with 16.76% in the coming years.
PEG (NY)0.23
PEG (5Y)N/A
EPS Next 2Y22.97%
EPS Next 3Y16.76%

0

5. Dividend

5.1 Amount

  • MD does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

PEDIATRIX MEDICAL GROUP INC

NYSE:MD (2/10/2026, 9:49:10 AM)

20.76

-0.13 (-0.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-03
Earnings (Next)02-19
Inst Owners98.9%
Inst Owner Change-0.29%
Ins Owners1.87%
Ins Owner Change-2.29%
Market Cap1.78B
Revenue(TTM)1.92B
Net Income(TTM)162.19M
Analysts78.67
Price Target23.12 (11.37%)
Short Float %3.62%
Short Ratio3.72
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.41%
Min EPS beat(2)21.14%
Max EPS beat(2)39.68%
EPS beat(4)4
Avg EPS beat(4)32.13%
Min EPS beat(4)21.14%
Max EPS beat(4)39.68%
EPS beat(8)7
Avg EPS beat(8)18.68%
EPS beat(12)7
Avg EPS beat(12)8.95%
EPS beat(16)9
Avg EPS beat(16)6.72%
Revenue beat(2)1
Avg Revenue beat(2)-0.77%
Min Revenue beat(2)-1.97%
Max Revenue beat(2)0.42%
Revenue beat(4)2
Avg Revenue beat(4)-0.67%
Min Revenue beat(4)-1.97%
Max Revenue beat(4)0.42%
Revenue beat(8)2
Avg Revenue beat(8)-2.24%
Revenue beat(12)2
Avg Revenue beat(12)-2.22%
Revenue beat(16)3
Avg Revenue beat(16)-2.43%
PT rev (1m)0%
PT rev (3m)35.32%
EPS NQ rev (1m)0%
EPS NQ rev (3m)16.45%
EPS NY rev (1m)0%
EPS NY rev (3m)16.25%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.9%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.13%
Valuation
Industry RankSector Rank
PE 10.18
Fwd PE 9.21
P/S 0.93
P/FCF 6.52
P/OCF 6.15
P/B 2
P/tB N/A
EV/EBITDA 7.03
EPS(TTM)2.04
EY9.83%
EPS(NY)2.25
Fwd EY10.85%
FCF(TTM)3.18
FCFY15.33%
OCF(TTM)3.38
OCFY16.27%
SpS22.39
BVpS10.37
TBVpS-4.42
PEG (NY)0.23
PEG (5Y)N/A
Graham Number21.82
Profitability
Industry RankSector Rank
ROA 7.37%
ROE 18.21%
ROCE 12.98%
ROIC 10.25%
ROICexc 13.79%
ROICexgc 251.95%
OM 12.2%
PM (TTM) 8.44%
GM N/A
FCFM 14.22%
ROA(3y)-1.5%
ROA(5y)-4.7%
ROE(3y)-4.21%
ROE(5y)-20.91%
ROIC(3y)7.83%
ROIC(5y)7.13%
ROICexc(3y)8.94%
ROICexc(5y)8.89%
ROICexgc(3y)78.23%
ROICexgc(5y)75.12%
ROCE(3y)9.91%
ROCE(5y)9.03%
ROICexgc growth 3Y26.95%
ROICexgc growth 5Y24.1%
ROICexc growth 3Y3.64%
ROICexc growth 5Y14.51%
OM growth 3Y-7.13%
OM growth 5Y-6.94%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.87
Health
Industry RankSector Rank
Debt/Equity 0.65
Debt/FCF 2.2
Debt/EBITDA 2.24
Cap/Depr 72.01%
Cap/Sales 0.86%
Interest Coverage 250
Cash Conversion 112.59%
Profit Quality 168.57%
Current Ratio 1.83
Quick Ratio 1.83
Altman-Z 2.15
F-Score8
WACC8.81%
ROIC/WACC1.16
Cap/Depr(3y)81.28%
Cap/Depr(5y)89.11%
Cap/Sales(3y)1.42%
Cap/Sales(5y)1.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)56.92%
EPS 3Y-2.95%
EPS 5Y-15.01%
EPS Q2Q%52.27%
EPS Next Y44.07%
EPS Next 2Y22.97%
EPS Next 3Y16.76%
EPS Next 5Y7.64%
Revenue 1Y (TTM)-4.21%
Revenue growth 3Y1.74%
Revenue growth 5Y2.49%
Sales Q2Q%-3.58%
Revenue Next Year-4.52%
Revenue Next 2Y-0.98%
Revenue Next 3Y0.1%
Revenue Next 5Y2.71%
EBIT growth 1Y42.45%
EBIT growth 3Y-5.51%
EBIT growth 5Y-4.62%
EBIT Next Year70.96%
EBIT Next 3Y20.58%
EBIT Next 5YN/A
FCF growth 1Y104.91%
FCF growth 3Y60.68%
FCF growth 5Y-11.42%
OCF growth 1Y73.9%
OCF growth 3Y39.11%
OCF growth 5Y-10.4%

PEDIATRIX MEDICAL GROUP INC / MD FAQ

What is the ChartMill fundamental rating of PEDIATRIX MEDICAL GROUP INC (MD) stock?

ChartMill assigns a fundamental rating of 5 / 10 to MD.


What is the valuation status for MD stock?

ChartMill assigns a valuation rating of 9 / 10 to PEDIATRIX MEDICAL GROUP INC (MD). This can be considered as Undervalued.


How profitable is PEDIATRIX MEDICAL GROUP INC (MD) stock?

PEDIATRIX MEDICAL GROUP INC (MD) has a profitability rating of 6 / 10.


What are the PE and PB ratios of PEDIATRIX MEDICAL GROUP INC (MD) stock?

The Price/Earnings (PE) ratio for PEDIATRIX MEDICAL GROUP INC (MD) is 10.18 and the Price/Book (PB) ratio is 2.